Elixxer Stock Current Liabilities
| ELXR Stock | CAD 1.15 0.00 0.00% |
Elixxer fundamentals help investors to digest information that contributes to Elixxer's financial success or failures. It also enables traders to predict the movement of Elixxer Stock. The fundamental analysis module provides a way to measure Elixxer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elixxer stock.
Total Current Liabilities is likely to climb to about 8.6 M in 2024. Non Current Liabilities Total is likely to climb to about 4.4 M in 2024. Elixxer | Current Liabilities |
Elixxer Company Current Liabilities Analysis
Elixxer's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Elixxer Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Elixxer has a Current Liabilities of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The current liabilities for all Canada stocks is 100.0% higher than that of the company.
Elixxer Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elixxer's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Elixxer could also be used in its relative valuation, which is a method of valuing Elixxer by comparing valuation metrics of similar companies.Elixxer is currently under evaluation in current liabilities category among its peers.
Elixxer Fundamentals
| Return On Equity | -10.14 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 21.92 M | ||||
| Shares Outstanding | 11.34 M | ||||
| Shares Owned By Institutions | 32.04 % | ||||
| Number Of Shares Shorted | 238 | ||||
| Price To Book | 2.67 X | ||||
| Price To Sales | 767,774 X | ||||
| Revenue | 82.13 K | ||||
| Gross Profit | 42.41 K | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (6.17 M) | ||||
| Cash And Equivalents | 969.92 K | ||||
| Total Debt | 4.41 M | ||||
| Debt To Equity | 1.96 % | ||||
| Current Ratio | 0.06 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (2.35 M) | ||||
| Short Ratio | 0.67 X | ||||
| Earnings Per Share | (1.02) X | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 13.05 M | ||||
| Total Asset | 5.37 M | ||||
| Retained Earnings | (80.5 M) | ||||
| Working Capital | (4.81 M) | ||||
| Net Asset | 5.37 M |
About Elixxer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elixxer's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elixxer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elixxer based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elixxer Stock Analysis
When running Elixxer's price analysis, check to measure Elixxer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elixxer is operating at the current time. Most of Elixxer's value examination focuses on studying past and present price action to predict the probability of Elixxer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elixxer's price. Additionally, you may evaluate how the addition of Elixxer to your portfolios can decrease your overall portfolio volatility.